2024-03-07T03:49:27.261Z

GS-US-587-6156

GS-US-587-6156
Colorectal cancer

A Phase 2, Randomized, Open-Label Study of Magrolimab Given Together With FOLFIRI/ BEV in Patients with Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC)

A Phase 2, Randomized, Open-Label Study of Magrolimab Given Together With FOLFIRI/ BEV in Patients with Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) (ELEVATE CRC)

Trial overview

Topic

Advanced inoperable metastatic colorectal cancer

Trial registration

Number: NCT05330429

Study details

The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).

The primary objectives of this study are: (safety run-in cohort) to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).

Further information

Click here for further information

Location

GenesisCare North Shore – PI: Dr David Chan

 

GenesisCare North Shore – PI: Dr David Chan   :::

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.